retatrutide trial safety Efficacy and of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 A Study of Retatrutide (LY3437943)

Budget-conscious travelers can use USB-powered medical coolers throughout their stay, eliminating hotel refrigerator dependence entirely

Only 13 state Medicaid programs cover GLP-1 for obesity as of January 2026

Researchers who struggled with exercise at their starting weight find that 20 to 30 pounds of loss opens up new possibilities for movement, creating a positive feedback loop that accelerates further progress

These numbers were unprecedented when first published and set the benchmark that all subsequent obesity treatments have been measured against

Remove the safety caps from the top and bottom of syringe

Most quality problems stem from unclear specifications rather than deliberate fraud